BAMM · Body & Mind Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.41M | $4.43M | $5.46M | $7.31M | $7.74M | $7.83M | $7.88M | $8.05M | $7.57M | $7.16M |
| Cost of Revenue | $2.44M | $2.41M | $3.42M | $5.24M | $5.48M | $6.19M | $4.97M | $5.02M | $4.08M | $2.88M |
| Gross Profit | $1.96M | $2.02M | $2.04M | $2.08M | $2.27M | $1.64M | $2.91M | $3.02M | $3.49M | $4.27M |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | $65.6K | - | - | $234.7K | - | - | - | $3.57M |
| Total Operating Expenses | ($3.30M) | ($2.87M) | $3.20M | ($3.71M) | ($4.03M) | ($3.62M) | $4.25M | ($3.99M) | $3.17M | - |
| D&A | $94.0K | $96.0K | $96.0K | $351.2K | $362.6K | $362.1K | $445.7K | $437.8K | $331.5K | $289.9K |
| Operating Income | ($1.34M) | ($844.1K) | ($1.16M) | ($1.63M) | ($970.8K) | ($1.98M) | ($1.34M) | ($1.31M) | $24.9K | $708.0K |
| Interest Expense | - | - | - | - | $425.1K | $381.4K | $338.2K | $340.0K | $338.8K | $1.4K |
| Income Tax | $388.4K | $532.5K | $837.9K | $939.0K | ($620.1K) | $626.1K | $821.3K | ($1.42M) | $702.2K | $976.5K |
| Net Income | ($2.54M) | ($168.8K) | $163.8K | ($3.61M) | ($2.74M) | ($2.95M) | ($2.46M) | ($2.72M) | ($677.3K) | ($353.6K) |
| EPS - Basic | - | - | ($0.03) | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291.5K | $1.46M | $891.0K | $1.51M | $4.62M | $1.30M | $3.71M | $4.62M | $7.43M | $7.37M |
| Accounts Receivable | $41.9K | $34.2K | $638.2K | $591.3K | - | - | - | - | - | - |
| Inventory | $632.6K | $643.7K | $2.10M | $2.31M | $2.80M | $3.26M | $3.88M | $4.07M | $3.37M | $2.94M |
| Accounts Payable | $3.34M | $2.91M | $3.04M | $2.76M | $2.69M | $2.88M | $2.49M | $1.99M | $1.55M | $1.69M |
| Current Assets | $4.70M | $5.81M | $5.67M | $9.28M | $8.11M | $6.69M | $8.00M | $12.50M | $15.02M | $14.31M |
| Total Assets | $16.19M | $18.00M | $17.51M | $21.21M | $32.59M | $29.00M | $31.03M | $53.93M | $48.98M | $48.13M |
| Current Liabilities | $10.11M | $11.77M | $9.87M | $7.67M | $8.47M | $7.63M | $6.62M | $8.42M | $6.65M | $6.45M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $28.12M | $27.77M | $27.01M | $30.55M | $27.62M | $21.88M | $20.92M | $21.20M | $14.58M | $13.78M |
| Stockholders' Equity | ($13.09M) | ($10.87M) | ($10.52M) | ($10.27M) | $4.30M | $6.54M | $9.63M | $32.44M | $34.40M | $34.35M |
| Retained Earnings | ($69.60M) | ($67.00M) | ($66.75M) | ($66.83M) | ($51.70M) | ($48.86M) | ($45.80M) | ($20.79M) | ($17.92M) | ($17.13M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($1.12M) | - | - | ($589.1K) | - | - | $256.5K | - |
| Investing Cash Flow | - | - | $8.04M | - | - | $107.0K | - | - | ($232.1K) | - |
| Financing Cash Flow | - | - | ($7.18M) | - | - | ($8) | - | - | ($1.8K) | - |
| CapEx | - | - | $4.6K | - | - | $8.3K | - | - | $15.7K | - |
| Free Cash Flow | - | - | ($1.12M) | - | - | ($597.4K) | - | - | $240.9K | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 44.6% | 45.7% | 37.4% | 28.4% | 29.3% | 20.9% | 36.9% | 37.6% | 46.1% | 59.7% |
| Operating margin | -30.4% | -19.1% | -21.3% | -22.3% | -12.5% | -25.3% | -17.0% | -16.2% | 0.3% | 9.9% |
| EBITDA margin | -28.3% | -16.9% | -19.6% | -17.5% | -7.9% | -20.6% | -11.3% | -10.8% | 4.7% | 13.9% |
| Net margin | -57.6% | -3.8% | 3.0% | -49.3% | -35.4% | -37.7% | -31.3% | -33.8% | -8.9% | -4.9% |
| Free cash flow margin | - | - | -20.6% | - | - | -7.6% | - | - | 3.2% | - |
| FCF / Net income | - | - | -6.86 | - | - | 0.20 | - | - | -0.36 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | 1.2% | - | - | 3.0% | - | - | - | 49.8% |
| Effective tax rate | - | 146.4% | 83.6% | - | - | - | - | - | 2817.9% | 156.8% |
| Return on assets | -15.7% | -0.9% | 0.9% | -17.0% | -8.4% | -10.2% | -7.9% | -5.0% | -1.4% | -0.7% |
| Return on equity | 19.4% | 1.6% | -1.6% | 35.1% | -63.8% | -45.2% | -25.6% | -8.4% | -2.0% | -1.0% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.46 | 0.49 | 0.57 | 1.21 | 0.96 | 0.88 | 1.21 | 1.48 | 2.26 | 2.22 |
| Quick ratio | 0.40 | 0.44 | 0.36 | 0.91 | 0.63 | 0.45 | 0.62 | 1.00 | 1.75 | 1.76 |
| Cash ratio | 0.03 | 0.12 | 0.09 | 0.20 | 0.54 | 0.17 | 0.56 | 0.55 | 1.12 | 1.14 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | -2.3x | -5.2x | -4.0x | -3.8x | 0.1x | 521.7x |
| Equity multiplier | -1.24 | -1.66 | -1.66 | -2.06 | 7.59 | 4.44 | 3.22 | 1.66 | 1.42 | 1.40 |
| Liabilities / Assets | 1.74 | 1.54 | 1.54 | 1.44 | 0.85 | 0.75 | 0.67 | 0.39 | 0.30 | 0.29 |
| Efficiency | ||||||||||
| Asset turnover | 0.27 | 0.25 | 0.31 | 0.34 | 0.24 | 0.27 | 0.25 | 0.15 | 0.15 | 0.15 |
| Inventory turnover | 3.86 | 3.74 | 1.62 | 2.27 | 1.96 | 1.90 | 1.28 | 1.23 | 1.21 | 0.98 |
| Days sales outstanding | 3d | 3d | 43d | 30d | - | - | - | - | - | - |
| Days inventory outstanding | 95d | 98d | 225d | 161d | 187d | 192d | 285d | 296d | 302d | 372d |
| Days payable outstanding | 500d | 441d | 325d | 193d | 180d | 170d | 183d | 144d | 138d | 214d |
| Cash conversion cycle | -402d | -341d | -58d | -2d | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -39.7% | -42.8% | -30.3% | -7.2% | -3.8% | 3.4% | 10.1% | 27.4% | 43.0% | 580.0% |
| Revenue CAGR (3y) | -14.9% | -11.2% | 1.0% | 90.8% | 70.1% | 75.8% | 85.3% | 88.8% | 78.7% | 108.5% |
| Revenue CAGR (5y) | 28.9% | 29.9% | 32.7% | 56.1% | - | - | - | - | - | - |
| Gross profit growth (YoY) | -5.4% | -10.8% | 24.5% | -28.5% | -25.1% | -53.0% | -32.0% | 10.0% | 93.9% | - |
| Operating income growth (YoY) | 17.7% | 13.1% | 41.2% | -21.5% | 25.7% | - | - | - | - | - |
| Net income growth (YoY) | 29.7% | 93.8% | - | -46.6% | -0.7% | -336.0% | -596.2% | -127.8% | 14.5% | 69.4% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | -88.0% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -27.4% | - | - | - | -86.8% | -81.0% | -72.0% | -0.8% | 2.3% | 2.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-07-31.
Product / service
$17.75M totalRetail$17.75M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing BODY & MIND INC. against the 5 most active filers in the same SIC group.